AU2011298315B2 — Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same

USPTO Abstract

A drug product comprising: a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy} hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol, or a salt thereof, and (II) (6α,11ß,16α,17α)-6,9-difluoro- 17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien- 7-yl 2- furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.